Detailed Roche study results muddy another Alzheimer's hypothesis
Bio Pharma Dive
NOVEMBER 11, 2021
Data presented at an Alzheimer's meeting raised more questions about the seeming benefit of Roche and AC Immune's drug semorinemab, which they claim is the first of its kind to slow deterioration of memory.
Let's personalize your content